ClinicalTrials.gg
Active, not recruitingNCT04393649Updated Feb 23, 2024

First Level Socio-geriatric Evaluation: ESOGER Databank

An observational study in COVID, Social Isolation and Anxiety, sponsored by Jewish General Hospital. Active, not recruiting at 1 site in Canada. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2024-02-23.

Sponsored by Jewish General Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20,000
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Social Isolation with a site in Canada — 9 open to participants now, 10 under way, none of them phase 3. Social Isolation · Canada.

Started
2020
with 2 others
Observational
Only one
of the 30
Registered
9th of 30
by date
Lead sponsor
3 of 30
Jewish General Hospital

Among the 30 studies in Social Isolation with a site in Canada, this one is one of 3 that started in 2020, is the only observational one, and was the 9th registered.

Social Isolation

237 studies on the registry are indexed under Social Isolation; 61 are open to participants now.

Browse Social Isolation studies →

Open to participants now

9 of the 30 studies in Social Isolation with a site in Canada are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 34 Social Isolation studies recruiting now, 22 (65%) set no upper age limit and 6 (18%) stop at 75 or younger; 4 take children under 18; 18 take healthy volunteers.

This study: 70 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Social Isolation with a site in Canada, or all of them as a file.
02

Study summary

Coronavirus disease 2019 (COVID-19) is an infectious disease. Physical distancing is one of the most effective ways to reduce the spread of COVID-19, but this key prevention intervention may have adverse consequences on older adults living at home. Screening older adults living at home and at risk for adverse consequences of physical and social distancing is, therefore, a priority in order to prevent their occurrence. ESOGER ("Evaluation Social et GERiatrique") is a clinical tool designed to: 1) screen the risk-levels for adverse consequences related to COVID-19 physical distancing and 2) to continue appropriate preventive interventions in older adults living at home including frail older patients and older community dwellers. Experience cumulated during the past two weeks revealed that ESOGER could be improved, in order to be more effective and efficient for the prevention of adverse consequences related to COVID-19 physical distancing. This improvement is based on two key components: 1) Comments of Montreal ESOGER users and 2) Analysis of data. Because at this time no information is saved and stored, there is a need to save and store ESOGER information and create the ESOGER databank.

03

Conditions studied

  • COVID
  • Social Isolation
  • Anxiety
  • Frailty
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

All the older patients and community dwellers living at home in Montreal contacted by the researchers and corresponding to the criteria.

The project is about a constitution of a databank.

Eligibility criteria

The inclusion criteria are:

  1. Older (i.e., 70-years-old and over) adults OR caregiver living at home with an adult answering to inclusion criteria
  2. Living and staying at home because of physical and social distancing
  3. Understanding and writing the different languages of the recruitment centre (i.e., French, English, Chinese.)
  4. Agree to participate in the study

The exclusion criteria are:

  1. A concomitant participation to another medical trial
  2. Living in semi-autonomous residence or CHSLD
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20,000 participants (actual)
Target follow-up
6 Months
Patient registry
Yes

Groups and cohorts

  • Older patients / community dwellers

    The inclusion criteria are: 1. Older (i.e., 70-years-old and over) adults OR caregiver living at home with an adult answering to inclusion criteria 2. Living and staying at home because of physical and social distancing 3. Understanding and writing the different languages of the recruitment centre (i.e., French, English, Chinese.) 4. Agree to participate in the study The exclusion criteria are: 1. A concomitant participation to another medical trial 2. Living in semi-autonomous residence or CHSLD

    Other: ESOGER

Interventions

  • OtherESOGER

    Questionnaire

06

What researchers measure

Primary outcomes

  1. COVID-19 symptoms

    presence or not of fever, cough and shortness of breath (binary question)

    Time frame: 1 day

  2. issues related to medication and food delivery and access to home care

    presence or not of a rupture of access to food, medication and home care (binary question)

    Time frame: 1 day

  3. physical frailty

    Questionnaire Emergency Room Evaluation and Recommandation (ER2), score from 0 = no risk of frailty to 14 = high risk of frailty)

    Time frame: 1 day

  4. psychological frailty

    anxiety Verbal analogic scale, score from 0 = no anxiety to 10 = extremely anxious)

    Time frame: 1 day

Secondary outcomes

  1. Caregiver burden

    Zarit scale, score from 0 = no caregiver burden to 16 = high caregiver burden)

    Time frame: 1 day

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2020 (actual). Primary completion is estimated for Apr 2027, 83 months after the start.

Of 17 observational studies under Social Isolation, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 44. This study's planned 83 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2020
First posted
May 19, 2020
StartActual
Apr 20, 2020
Primary completionEst.
Apr 19, 2027
CompletionEst.
Apr 19, 2027
Last update
Feb 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04393649
Lead sponsor
Jewish General Hospital
Responsible party
Olivier Beauchet (Senior clinician researcher, Jewish General Hospital) — Principal investigator
First posted
May 19, 2020
Start date
Apr 20, 2020
Primary completion
Apr 19, 2027 (estimated)
Completion
Apr 19, 2027 (estimated)
Last update
Feb 23, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion